Company Has Six Presentations at AACR Highlighting Clinical and Preclinical Data
BURLINGAME, Calif., March 20, 2017 (GLOBE NEWSWIRE) — Corvus Pharmaceuticals, Inc. (Nasdaq:CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology therapies, today announced that it will present interim data from its ongoing Phase 1/1b study of CPI-444 as a single agent and in combination with Genentech’s Tecentriq® (atezolizumab) in an oral plenary session at the American Association for Cancer Research (AACR) Annual Meeting 2017, which is taking place April 1-5 in Washington, D.C. The Company will also present preclinical and clinical data on CPI-444, as well as preclinical data on its investigational humanized monoclonal anti-CD73 antibody, in poster presentations. In a separate invited oral presentation, CPI-444 will be featured as a novel oral checkpoint inhibitor of adenosine mediated suppression of tumor immunity. The following are details for the six oral and poster presentations. The abstract for the oral plenary session will be available on the AACR website on March 31 at 4:30 p.m. ET.
Abstract #: CT119Title: CPI-444, an oral adenosine A2a receptor (A2AR) antagonist, demonstrates clinical activity in patients with advanced solid tumors Presenter: Leisha Emens, M.D., Ph.D., associate professor of oncology, John Hopkins Sidney Kimmel Comprehensive Cancer CenterSession Type: Oral PlenaryPresentation Date and Time: Tuesday, April 4, 10:30 a.m.-12:45 p.m. ETLocation: Ballroom C, Level 3, Washington Convention Center
Title: CPI-444 – A Novel Oral Checkpoint Inhibitor of Adenosine Mediated Suppression of Tumor ImmunityPresenter: Ian McCaffery, Ph.D., Corvus PharmaceuticalsSession Type: Invited OralPresentation Date and Time: Saturday, April 1, 3:15-5:15 p.m. ETLocation: Ballroom A-B, Level 3, Washington Convention Center
Abstract #: 5593/Poster #: 25Title: Inhibition of A2AR induces anti-tumor immunity alone and in combination with anti-PD-L1 in preclinical and clinical studiesPresenter: Stephen Willingham, Ph.D., Corvus PharmaceuticalsPresentation Date and Time: Wednesday, April 5, 8:00 a.m-12:00 p.m. ETLocation: Convention Center, Halls A-C, Poster Section 24
Abstract #: 5598/Poster #: 30Title: Adenosine signaling through A2AR limits the efficacy of anti-CTLA4 and chemotherapy in preclinical modelsPresenter: Po Y. Ho, Corvus PharmaceuticalsPresentation Date and Time: Wednesday, April 5, 8:00 a.m-12:00 p.m. ETLocation: Convention Center, Halls A-C, Poster Section 24
Abstract #: 5579/Poster #: 11Title: Strategic inhibition of adenosine A2A receptor (A2AR) by CPI-444 improves CD8+:Treg ratios and enhances T-cell killing of a HER-2/neu expressing murine tumorPresenter: Blake A. Scott, Johns Hopkins University School of MedicinePresentation Date and Time: Wednesday, April 5, 8:00 a.m-12:00 p.m. ETLocation: Convention Center, Halls A-C, Poster Section 24
Abstract #: 5577/Poster #: 9Title: A novel CD73-blocking antibody reduces production of immunosuppressive adenosine and restores T-cell functionPresenting Author: Emily Piccione, Ph.D., Corvus Pharmaceuticals Presentation Date and Time: Wednesday, April 5, 8:00 a.m.-12:00 p.m. ETLocation: Convention Center, Halls A-C, Poster Section 24
About Corvus PharmaceuticalsCorvus Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development and commercialization of small molecule and antibody agents that target the immune system to treat patients with cancer. These agents block or modify crucial immune checkpoints and reprogram immune T-cells. Corvus’ lead product, CPI-444, is a checkpoint inhibitor that is designed to disable a tumor’s ability to subvert attack by the immune system by inhibiting adenosine in the tumor microenvironment. CPI-444 is a small molecule that is taken orally. CPI-444 is currently being evaluated in a multicenter Phase 1/1b clinical trial in patients with various solid tumors. This successive expansion cohort trial is examining the activity of CPI-444 both as a single agent and in combination with Genentech’s Tecentriq (atezolizumab), an anti-PD-L1 antibody. Corvus is conducting the trial with Genentech, a member of the Roche Group, under a clinical trial collaboration the two companies entered into in October 2015. For more information, visit www.corvuspharma.com.
Tecentriq® is a registered trademark of Genentech.
SVP, Chief Business Officer
Corvus Pharmaceuticals, Inc.